US President Donald J Trump launched the ‘TrumpRx’ website in February 2026. It is designed to connectAmericans directly with manufacturers and enable access to lower-priced prescription drugs.
TrumpRx was launched with the statement: ‘America was being overcharged for medicine. The same drugs, made in the same factories, at the same dosages, are costing Americans up to 1000% more than in any other country. This is unacceptable’.
As announced in 2025 [1], Trump struck deals with major drugmakers to list medications on the site at steeply discounted prices.
The administration stated that the site offers discounted prices from more than a dozen drugmakers, including Pfizer and Novo Nordisk.
As an example of possible savings, with TrumpRx a four-week supply of semaglutide provided by the Wegovy Pen costs US$199 for the first two months; it then increases to US$349. The drug’s approximate list price is US$1,349.
To receive the medication, users are required to print out a coupon and fill the prescription at a participating pharmacy.
The discounted prices are most likely to benefit uninsured Americans, people with high deductibles, and those whose medications are not covered by their insurance, such as certain weight loss or IVF drugs. Those with insurance are advised to check with their co-pay before turning to TrumpRx.
Products listed are both small-molecule and biological drugs. At the time of writing, the site lists only one biosimilar drug product, Abrilada (adalimumab-afzb) [2], approved as an interchangeable biosimilar to Humira in October 2023 [2].
The launch of TrumpRx is a direct consequence of the administration’s implementation of President Trump’s Executive Order, ‘Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients’ [3].
Related articles
Trump’s ‘One Big Beautiful Bill’: implications for US health care
President Trump issues executive order to lower drug prices
Second wave of drugs selected for Medicare price negotiation
References
1. GaBI Online - Generics and Biosimilars Initiative. Direct-to-Consumer TrumpRx aims to slash US drug prices [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2026 Apr 8]. Available from: www.gabionline.net/pharma-news/direct-to-consumer-trumprx-aims-to-slash-us-drug-prices
2. GaBI Online - Generics and Biosimilars Initiative. FDA grants interchangeable designation to adalimumab biosimilar Abrilada [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2026 Apr 8]. Available from: www.gabionline.net/biosimilars/news/fda-grants-interchangeable-designation-to-adalimumab-biosimilar-abrilada
3. GaBI Online - Generics and Biosimilars Initiative. US EO: delivering Most-Favored-Nation Prescription Drug Pricing to American patients [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2026 Apr 8]. Available from: www.gabionline.net/policies-legislation/us-eo-delivering-most-favored-nation-prescription-drug-pricing-to-american-patients
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2026 Pro Pharma Communications International. All Rights Reserved.
0
Post your comment